Biomind Labs Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BMNDF research report →
Companywww.biomindlabs.com
Biomind Labs Inc. , a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment.
- CEO
- Alejandro Antalich
- IPO
- 2021
- Employees
- 5
- HQ
- Canelones, UY
Price Chart
Valuation
- Market Cap
- $9.31M
- P/E
- -10.41
- P/S
- 0.00
- P/B
- -5.97
- EV/EBITDA
- -12.14
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 62.51%
- ROIC
- 94.40%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-865,298 · -232.19%
- EPS
- $-0.01 · -226.47%
- Op Income
- $-861,418
- FCF YoY
- 80.61%
Performance & Tape
- 52W High
- $0.70
- 52W Low
- $0.01
- 50D MA
- $0.08
- 200D MA
- $0.06
- Beta
- 5.40
- Avg Volume
- 369
Get TickerSpark's AI analysis on BMNDF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BMNDF Coverage
We haven't published any research on BMNDF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BMNDF Report →